公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 北京康辰药业股份有限公司 2025 年第三季度报告 证券代码：603590 证券简称：康辰药业 北京康辰药业股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 231,351,151.37 | -4.12 | 6 ...

康辰药业公告，第三季度营收为2.31亿元，同比下降4.12%；净利润为3683.4万元，同比增长9.06%。前 三季度营收为6.92亿元，同比增长7.10%；净利润为1.28亿元，同比增长13.19%。 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-067 北京康辰药业股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京康辰药业股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召 开的第四届董事会第十三次会议、第四届监事会第十一次会议审议通过《关于使 用闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币 3 亿元 的闲置募集资金适时进行现金管理，该额度自公司董事会审议通过之日起 12 个 月内有效，并在有效期内可循环滚动使用。具体内容详见公司于 2024 年 10 月 30 日在上海证券交易所网站及指定信息披露媒体披露的《康辰药业关于使用闲 置募集资金进行现金管理的公告》（公告编号：临 2024-065）。 截至本公告披露日，公司使用部分闲置募集资金购买的现金管理产品已赎回， 募集资金本金及理财收益已归还至募集资金账户，具体情况如下： | 单位：万元 | | --- | 北京康辰药业股份有限公司董事会 | 序 | ...

10月24日，康辰药业大宗交易成交4.7万股，成交额203.93万元，占当日总成交额的2.05%，成交价43.39 元，较市场收盘价48.41元折价10.37%。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-24 | 慶辰药业 | 603590 | 43.39 | 203.93 | 4.7 | 机构专用 | 我們都覺覺 | KO | ...

序号 股东名称 持股数量（股） 占公司总股本比例（%） 1 刘建华 49,517,760 31.07 2 北京沐仁投资管理有限公司 16,245,600 10.19 3 北京普华基业投资顾问中心（有限合伙） 9,600,000 6.02 4 张铭杰 4,167,200 2.62 5 杨永康 2,017,401 1.27 6 中国建设银行股份有限公司－前海开源 沪港深优势精选灵活配置混合型证券投 资基金 1,744,500 1.09 一、前十大股东持股情况 证券代码：603590 证券简称：康辰药业 公告编号：临 2025-066 北京康辰药业股份有限公司 关于回购股份事项前十大股东和 前十大无限售条件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京康辰药业股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日召开 第四届董事会第二十次会议、第四届监事会第十六次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，具体内容详见公司于 2025 年 1 月 16 日在上海证券交易 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) announced a significant change in shareholder equity, with major shareholder Liu Jianhua reducing his stake by 1,911,900 shares, resulting in a decrease in ownership from 46.65% to 45.45% [1][3]. Shareholder Changes - Liu Jianhua sold a total of 1,911,900 shares through centralized bidding and block trading on October 20, 2025, reducing his holdings from 74,341,860 shares to 72,429,960 shares [1]. - The total cash raised from this transaction amounted to approximately 97.37 million yuan, based on an average share price of 50.93 yuan on the transaction date [2]. Shareholding Structure - Before the transaction, Liu Jianhua held 48,496,260 shares (30.43%), which decreased to 46,584,360 shares (29.23%) post-transaction [3]. - Other shareholders, such as Beijing Muren Investment Management Co., Ltd. and Beijing Puhua Jiyie Investment Consulting Center (Limited Partnership), maintained their respective holdings of 10.19% and 6.02% without any changes [3]. Company Background - Kangchen Pharmaceutical was listed on the Shanghai Stock Exchange on August 27, 2018, with an initial issuance of 40 million shares, accounting for 25% of the total share capital post-issuance [4]. - The company raised a total of 973.6 million yuan, with a net fundraising amount of approximately 891.43 million yuan, aimed at various projects including innovative drug research and development [4].

Core Viewpoint - The announcements detail significant shareholder activities, including a reduction in shareholding by a major shareholder and the initiation of a share buyback program by the company [3][7]. Group 1: Shareholder Equity Changes - Major shareholder Liu Jianhua reduced his holdings by 1,911,900 shares on October 20, 2025, bringing his total shares from 74,341,860 to 72,429,960, which is a decrease in ownership percentage from 46.65% to 45.45% [3]. - This equity change touches the 1% threshold and is part of a previously disclosed reduction plan, not triggering a mandatory tender offer [3][4]. - The reduction is characterized as a normal divestment and will not significantly impact the company's governance structure or ongoing operations [3][4]. Group 2: Share Buyback Program - The company approved a share buyback plan on October 15, 2025, with a total budget between RMB 50 million and RMB 100 million, and a maximum buyback price of RMB 82 per share [7]. - As of October 20, 2025, the company has repurchased 377,400 shares, representing 0.24% of the total share capital, with a total expenditure of RMB 19,150,565 [8]. - The buyback is intended for employee stock ownership plans or equity incentives and will be conducted within a 12-month period following the board's approval [7][8].

Core Viewpoint - Kangchen Pharmaceutical announced its first share repurchase on October 20, 2025, through centralized bidding, acquiring 377,400 shares, which represents 0.24% of the company's total share capital [2] Summary by Category - **Share Repurchase Details** - The company repurchased 377,400 shares [2] - The repurchased shares account for 0.24% of the total share capital [2]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) announced its first share repurchase through centralized bidding on October 20, 2025, indicating a strategic move to enhance shareholder value [1] Summary by Categories Share Repurchase Details - The company repurchased a total of 377,400 shares, which represents 0.24% of the company's total share capital [1] - The highest purchase price was 51.40 CNY per share, while the lowest was 49.69 CNY per share [1] - The total amount paid for the repurchase was 19.15 million CNY [1]